Development of ST-246 for Treatment of Poxvirus Infections
Author Information
Author(s): Jordan Robert, Leeds Janet M., Tyavanagimatt Shanthakumar, Hruby Dennis E.
Primary Institution: SIGA Technologies
Hypothesis
ST-246 is being developed as a therapeutic to treat pathogenic orthopoxvirus infections in humans.
Conclusion
ST-246 has shown to be safe and effective in treating orthopoxvirus infections in both animal models and human clinical trials.
Supporting Evidence
- ST-246 was effective in protecting multiple animal species from lethal orthopoxvirus challenge.
- Human phase I clinical trials showed that ST-246 is safe and well tolerated in healthy volunteers.
- ST-246 inhibits extracellular virus production, which is crucial for virus spread.
Takeaway
ST-246 is a new medicine that helps people fight off certain viruses that can make them very sick, like smallpox.
Methodology
The study involved high throughput screening of chemical compounds for antiviral activity against orthopoxviruses, followed by preclinical and clinical trials to assess safety and efficacy.
Limitations
The study primarily focuses on animal models and may not fully predict human responses.
Participant Demographics
Healthy human volunteers were included in the clinical trials.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website